Every obesity drug candidate in clinical development.
Approved drugs, submitted filings, Phase 3 and Phase 2 candidates — with mechanism, latest readouts, and primary-source citations. Updated as data lands.
| Drug | Developer | Mechanism | Phase |
|---|---|---|---|
TirzepatideMounjaro / Zepbound | Eli Lilly | Dual GIP / GLP-1 receptor agonist | Approved |
SemaglutideOzempic / Wegovy / Rybelsus | Novo Nordisk | GLP-1 receptor agonist | Approved |
| Novo Nordisk | Amylin analog + GLP-1 receptor agonist (fixed-dose combination) | Submitted | |
OrforglipronFoundayo (expected) | Eli Lilly | Small-molecule GLP-1 receptor agonist (oral) | Submitted |
RetatrutideLY-3437943 | Eli Lilly | Triple GIP / GLP-1 / glucagon receptor agonist | Phase 3 |
SurvodutideBI 456906 | Boehringer Ingelheim / Zealand Pharma | Dual GLP-1 / glucagon receptor agonist | Phase 3 |
PemvidutideALT-801 | Altimmune | Dual GLP-1 / glucagon receptor agonist | Phase 2b |
Amycretin | Novo Nordisk | Single-molecule amylin / GLP-1 dual agonist (injectable + oral variants) | Phase 2 |
DanuglipronPF-06882961 | Pfizer | Small-molecule GLP-1 receptor agonist (oral) | Phase 2 |
Tirzepatide
Eli Lilly · ApprovedLatest readout: SURMOUNT-5 head-to-head vs semaglutide (NEJM 2025)
What's next: Approved — ongoing indication expansions (HFpEF, CKD, NASH)
Semaglutide
Novo Nordisk · ApprovedLatest readout: SELECT cardiovascular benefit (NEJM 2023)
What's next: Approved — ongoing indication expansions (HFpEF, CKD, Alzheimer's)
CagriSema (cagrilintide + semaglutide)
Novo Nordisk · SubmittedLatest readout: REDEFINE-1 (NEJM 2025): ~20.4% mean weight loss at 68 weeks
What's next: FDA approval 2026–2027 pending review
Orforglipron
Eli Lilly · SubmittedLatest readout: ATTAIN-1 (obesity) + ACHIEVE-1 (T2D) Phase 3 top-line positive late 2025
What's next: FDA approval late 2026 or 2027
Retatrutide
Eli Lilly · Phase 3Latest readout: Phase 2 (NEJM 2023): ~24.2% mean weight loss at 48 weeks on 12 mg
What's next: Phase 3 TRIUMPH readouts 2025–2026; FDA filing 2026; approval 2026–2027
Survodutide
Boehringer Ingelheim / Zealand Pharma · Phase 3Latest readout: Phase 2 (Lancet 2023): ~19% weight loss at 46 weeks on highest dose
What's next: Phase 3 SYNCHRONIZE readouts 2025–2026
Pemvidutide
Altimmune · Phase 2bLatest readout: MOMENTUM Phase 2: ~15.6% weight loss at 48 weeks on 2.4 mg
What's next: Phase 3 entry 2025–2026
Amycretin
Novo Nordisk · Phase 2Latest readout: Phase 1b oral amycretin: ~13% weight loss at 12 weeks
What's next: Phase 3 entry 2026; approval 2028+
Danuglipron
Pfizer · Phase 2Latest readout: Phase 2 results variable; Pfizer discontinued twice-daily formulation in 2023; once-daily formulation ongoing
What's next: Uncertain — Pfizer's oral GLP-1 path has hit multiple tolerability issues